Viatris Inc (VTRS) Reports Q4 Adjusted Net Earnings of $971M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Viatris Inc (VTRS) Reports Q4 Adjusted Net Earnings of $971M

Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future

February 28, 2022 6:00 AM EST

PITTSBURGH, Feb. 28, 2022 /PRNewswire/ --

Biocon Biologics Transaction Consists of Pre-tax Consideration of up to $3.335 billion, Including $2 billion in Upfront Cash, $1 billion of Convertible Preferred Equity Representing a Stake of at Least 12.9% in Biocon Biologics (on a Fully Diluted Basis), and up to $335 million of Additional Payments. Rajiv Malik, Viatris President, to Represent Viatris on Biocon Biologics Board. Transaction is Expected to Close in Second Half of 2022 Material Benefits of the Transaction Upon Closing Include: Crystalizes Value Accretion at Approximately Triple Current Standalone Multiple Nearly 2/3 in... More